Videos and Recordings - Technology
Take a virtual tour!
Learn about the next-generation Simoa biomarker detection technology that enables researchers to multiplex up to 10 analytes with unprecedented sensitivity.
Early Diagnosis Through Predictive Biomarkers, NonInvasive Testing
In an excerpt from a panel discussion which took place at MedCity CONVERGE on July 11, 2018, Quanterix Chairman and CEO Kevin Hrusovsky joins other key innovators to discuss game-changing biotech advancements and the future of healthcare.
President, CEO & Chairman of Quanterix
We're passionate about the work we do and believe we can transform today’s sick care into tomorrow’s precision healthcare.
Take a Virtual Tour
Quanterix' proprietary Simoa Bead Technology is based on the isolation of individual immunocomplexes on paramagnetic beads using standard ELISA reagents.
Interview with Kevin Hrusovsky, Chairman and CEO of Quanterix
Kevin Hrusovsky, Quanterix Chairman and CEO and Founder of Powering Precision Health, recently sat down with TetraScience CEO Alok Tayi to talk about the exciting work that Quanterix is doing in the area of clinical biomarkers and the business of diagnostics as well as a broader view
Disrupting Drug Development with Biomarkers and the Power of Precision Health
This presentation contains “forward-looking” statements that are based on our beliefs and assumptions and on information available to us as of the date of this presentation. Forward-looking statements include all statements that are not historical facts.
September 25, 2018
In a recent interview with Baystate Business, Quanterix Chairman and CEO and founder of Powering Precision Health, Kevin Hrusovsky explains the fundamentals of Quanterix technology and how it's disrupting the way healthcare is practiced.